Sutro Biopharma, Inc. (STRO)

Market Cap	522.70M +948.1%
Revenue (ttm)	102.48M +65.2%
Net Income	-191.09M
EPS	-22.49
Shares Out	16.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	296,978
Open	30.57
Previous Close	29.35
Day's Range	29.79 - 32.58
52-Week Range	5.23 - 32.58
Beta	1.31
Analysts	Buy
Price Target	27.33 (-13.38%)
Earnings Date	May 7, 2026

About STRO

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: STRO
• Website: https://www.sutrobio.com

Financial Performance

In 2025, Sutro Biopharma's revenue was $102.48 million, an increase of 65.18% compared to the previous year's $62.04 million. Losses were -$191.09 million, -15.99% less than in 2024.

Analyst Summary

According to 9 analysts, the average rating for STRO stock is "Buy." The 12-month stock price target is $27.33, which is a decrease of -13.38% from the latest price.

Price Target

$27.33

(-13.38% downside)

Analyst Consensus: Buy